Stock ACCD ACCOLADE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Accolade, Inc.

Equities

ACCD

US00437E1029

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-13 pm EDT 		5-day change 1st Jan Change
7.21 USD 0.00% Intraday chart for Accolade, Inc. -5.50% -39.97%
Apr. 30 Wells Fargo Cuts Price Target on Accolade to $10 From $12, Maintains Equalweight Rating MT
Apr. 26 Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wells Fargo Cuts Price Target on Accolade to $10 From $12, Maintains Equalweight Rating
MT
Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating
MT
Accolade : Investor Presentation
PU
Transcript : Accolade, Inc., Q4 2024 Earnings Call, Apr 25, 2024
Accolade, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended February 29, 2024
CI
Accolade: Fiscal Q4 Earnings Snapshot
AQ
Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2024
GL
Stifel Adjusts Accolade's Price Target to $13 From $15, Keeps Buy Rating
MT
Accolade to Announce Fiscal Fourth Quarter 2024 Financial Results
AQ
Accolade Wins 2024 Artificial Intelligence Excellence Award
PR
Accolade Promotes Kelsi McDonald Harris to Chief People Officer
PR
Accolade, Inc. Promotes Kelsi McDonald Harris to Chief People Officer and Senior Vice President
CI
Transcript : Accolade, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
Accolade To Present at Upcoming Investor Conferences
AQ
Leerink Partners Initiates Accolade at Outperform Rating With $16 Price Target
MT
Accolade Welcomes Kindbody to Trusted Partner Ecosystem
PR
Accolade Insider Sold Shares Worth $1,554,504, According to a Recent SEC Filing
MT
Transcript : Accolade, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM
Accolade Shares Surge After Raymond James Upgrade, Fiscal Q3 Results
MT
Raymond James Adjusts Accolade's Price Target to $16 From $12, Keeps Outperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACCD Stock
  4. News Accolade, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW